Biotechnology M&A » By The Online Investor Staff, updated Wed., Apr. 24, 8:55 PM
Recent mergers and acquisitions in the Biotechnology M&A category.
| This Slide: #53 of 83 |
Slide #53. BELLUS Health — Thallion Pharmaceuticals
Acquirer:
BELLUS Health (BLU.CA)
Acquiree:
Thallion Pharmaceuticals (TLN.CA)
Details:
BELLUS Health Inc. ("BELLUS Health") (TSX: BLU) today announced the consummation of the previously announced arrangement pursuant to which BELLUS Health has acquired all of the issued and outstanding common shares of Thallion Pharmaceuticals Inc. ("Thallion") (TSX-V: TLN) for a purchase price of $6.266 million or $0.1889 per common share, and the issuance of one contingent value right per common share.
BELLUS Health is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Co.'s primary product candidate, BLU-5937, is a selective and potentially antagonist of the P2X3 receptor, a clinically validated target to treat cough hypersensitivity. Co. is developing BLU-5937 for the treatment of adults with RCC.
Open the BLU.CA Page at The Online Investor »
BELLUS Health is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Co.'s primary product candidate, BLU-5937, is a selective and potentially antagonist of the P2X3 receptor, a clinically validated target to treat cough hypersensitivity. Co. is developing BLU-5937 for the treatment of adults with RCC.
Open the TLN.CA Page at The Online Investor »
|
|||||||||
|
|||||||||
 Free Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
